Appointment of Members of Senior Executive Services Performance Review Board., 55831 [2010-22794]
Download as PDF
<![CDATA[
jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 177 / Tuesday, September 14, 2010 / Notices
centralized review under Executive
Order 12866.
This action does not preempt or
modify any provision of state law; nor
does it impose enforcement
responsibilities on any state; nor does it
diminish the power of any state to
enforce its own laws. Accordingly, this
action does not have federalism
implications warranting the application
of Executive Order 13132.
The Deputy Administrator hereby
certifies that this action will have no
significant impact upon small entities
whose interests must be considered
under the Regulatory Flexibility Act, 5
U.S.C. 601 et seq. The establishment of
aggregate production quotas for
schedules I and II controlled substances
is mandated by law and by international
treaty obligations. The quotas are
necessary to provide for the estimated
medical, scientific, research and
industrial needs of the United States, for
export requirements and the
establishment and maintenance of
reserve stocks. While aggregate
production quotas are of primary
importance to large manufacturers, their
impact upon small entities is neither
negative nor beneficial. Accordingly, the
Deputy Administrator has determined
that this action does not require a
regulatory flexibility analysis.
This action meets the applicable
standards set forth in Sections 3(a) and
3(b)(2) of Executive Order 12988 Civil
Justice Reform.
This action will not result in the
expenditure by state, local, and tribal
governments, in the aggregate, or by the
private sector, of $126,400,000 or more
in any one year, and will not
significantly or uniquely affect small
governments. Therefore, no actions were
deemed necessary under the provisions
of the Unfunded Mandates Reform Act
of 1995.
This action is not a major rule as
defined by Section 804 of the Small
Business Regulatory Enforcement
Fairness Act of 1996. This action will
not result in an annual effect on the
economy of $100,000,000 or more; a
major increase in costs or prices; or
significant adverse effects on
competition, employment, investment,
productivity, innovation, or on the
ability of United States-based
companies to compete with foreignbased companies in domestic and
export markets.
Dated: September 2, 2010.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. 2010–22785 Filed 9–13–10; 8:45 am]
BILLING CODE 4410–09–P
VerDate Mar<15>2010
16:38 Sep 13, 2010
Jkt 220001
OFFICE OF NATIONAL DRUG
CONTROL POLICY
Appointment of Members of Senior
Executive Services Performance
Review Board.
Office of National Drug Control
Policy [ONDCP].
ACTION: Notice of Appointments.
AGENCY:
Heading: Appointment of Members of
Senior Executive Services Performance
Review Board.
SUMMARY: The following persons have
been appointed to the ONDCP Senior
Executive Service Performance Review
Board: Dr. Terry Zobeck, Ms. Martha
Gagne, Ms. Christine Leonard, and Mr.
Patrick Ward.
FOR FURTHER INFORMATION CONTACT:
Please direct any questions to Linda V.
Priebe, Deputy General Counsel (202)
395–6622, Office of National Drug
Control Policy, Executive Office of the
President, Washington, DC 20503.
Linda V. Priebe,
Deputy General Counsel.
[FR Doc. 2010–22794 Filed 9–13–10; 8:45 am]
BILLING CODE 3180–02–P
NUCLEAR REGULATORY
COMMISSION
Advisory Committee on the Medical
Uses of Isotopes: Call for Nominations
U.S. Nuclear Regulatory
Commission.
ACTION: Call for Nominations.
AGENCY:
The U.S. Nuclear Regulatory
Commission (NRC) is advertising for
nominations for the patients’ rights
advocate position on the Advisory
Committee on the Medical Uses of
Isotopes (ACMUI). Nominees should
have professional or personal
experience with or knowledge about
patient advocacy. Also, involvement or
leadership with patient advocacy
organizations is preferred.
DATES: Nominations are due on or
before November 15, 2010.
NOMINATION PROCESS: Submit an
electronic copy of resume or curriculum
vitae, along with a cover letter, to Ms.
Ashley Cockerham, ashley.
cockerham@nrc.gov. The cover letter
should describe the nominee’s current
involvement with patients’ rights
advocacy and express the nominee’s
interest in the position. Please ensure
that resume or curriculum vitae
includes the following information, if
applicable: education; certification;
professional association membership
SUMMARY:
PO 00000
Frm 00096
Fmt 4703
Sfmt 4703
55831
and committee membership activities;
and number of years, recentness, and
type of setting for patient advocacy.
FOR FURTHER INFORMATION CONTACT: Ms.
Ashley Cockerham, U.S. Nuclear
Regulatory Commission, Office of
Federal and State Materials and
Environmental Management Programs;
(240) 888–7129; ashley.cockerham@nrc.
gov.
SUPPLEMENTARY INFORMATION: The
patients’ rights advocate provides
advice to NRC staff on patients’ issues
associated with the regulation of
medical applications of byproduct
material. This advice includes ensuring
patients’ rights are represented during
the development and implementation of
NRC medical-use policy. This
individual is appointed based on his or
her professional and personal
experience with and/or knowledge
about patient advocacy, involvement
and/or leadership with patient advocacy
organizations, and other information
obtained in letters or during the
selection process. Nominees should
have the demonstrated ability to
establish effective work relationships
with peers and implement successful
approaches to problem solving and
conflict resolution. ACMUI members
currently serve a four-year term and
may be considered for reappointment to
an additional term. The current
membership is comprised of the
following professionals: (a) Nuclear
medicine physician; (b) nuclear
cardiologist; (c) nuclear medicine
physicist; (d) therapy medical physicist;
(e) radiation safety officer; (f) nuclear
pharmacist; (g) two radiation
oncologists; (h) patients’ rights
advocate; (i) Food and Drug
Administration representative; (j)
Agreement State representative; (k)
health care administrator; and (l)
diagnostic radiologist. For additional
information about membership on the
ACMUI, visit the ACMUI Membership
Web page, https://www.nrc.gov/aboutnrc/regulatory/advisory/acmui/
membership.html.
Nominees must be U.S. citizens and
be able to devote approximately 160
hours per year to Committee business.
Members are expected to attend semiannual meetings in Rockville, Maryland
and to participate in teleconferences, as
needed. Members who are not Federal
employees are compensated for their
service. In addition, these members are
reimbursed for travel and
correspondence expenses. Full-time
Federal employees are reimbursed for
travel expenses only.
Security Background Check: The
selected nominee will undergo a
E:\FR\FM\14SEN1.SGM
14SEN1
]]>Agencies
[Federal Register Volume 75, Number 177 (Tuesday, September 14, 2010)]
[Notices]
[Page 55831]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-22794]
=======================================================================
-----------------------------------------------------------------------
OFFICE OF NATIONAL DRUG CONTROL POLICY
Appointment of Members of Senior Executive Services Performance
Review Board.
AGENCY: Office of National Drug Control Policy [ONDCP].
ACTION: Notice of Appointments.
-----------------------------------------------------------------------
Heading: Appointment of Members of Senior Executive Services
Performance Review Board.
SUMMARY: The following persons have been appointed to the ONDCP Senior
Executive Service Performance Review Board: Dr. Terry Zobeck, Ms.
Martha Gagne, Ms. Christine Leonard, and Mr. Patrick Ward.
FOR FURTHER INFORMATION CONTACT: Please direct any questions to Linda
V. Priebe, Deputy General Counsel (202) 395-6622, Office of National
Drug Control Policy, Executive Office of the President, Washington, DC
20503.
Linda V. Priebe,
Deputy General Counsel.
[FR Doc. 2010-22794 Filed 9-13-10; 8:45 am]
BILLING CODE 3180-02-P
